Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2019
Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- Mass spectrometric imaging and quantitative analysis of theInorganic chemistry frontiers · 2025Article
- Article
- Review
- From surfing to diving into the tumor microenvironment through multiparametric imaging mass cytometry.Frontiers in immunology · 2025Review
- Highly Multiplexed Tissue Imaging in Precision Oncology and Translational Cancer Research.Cancer discovery · 2024Review
- Review
- Decoding the tumor microenvironment with spatial technologies.Nature immunology · 2023Review
- Chemical tagging mass spectrometry: an approach for single-cell omics.Analytical and bioanalytical chemistry · 2023Review
- Article
- Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity.Journal for immunotherapy of cancer · 2023Article
- Review
- Advances in mass cytometry and its applicability to digital pathology in clinical-translational cancer research.Advances in laboratory medicine · 2022Review
- Application of High-Throughput Imaging Mass Cytometry Hyperion in Cancer Research.Frontiers in immunology · 2022Review
- Navigating the cellular landscape in tissue: Recent advances in defining the pathogenesis of human disease.Computational and structural biotechnology journal · 2022Review
- Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery.Cancer immunology research · 2021Article
- HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase.Molecular cancer research : MCR · 2021Article
- Challenges and Opportunities in the Statistical Analysis of Multiplex Immunofluorescence Data.Cancers · 2021Review
- Spatially visualized single-cell pathology of highly multiplexed protein profiles in health and disease.Communications biology · 2021Article
- Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Using Imaging Mass Cytometry to Define Cell Identities and Interactions in Human Tissues.Frontiers in physiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 4 countries.
Funding
Abstract
purposeImaging mass cytometry (IMC) uses metal-conjugated antibodies to provide multidimensional, objective measurement of protein targets. We used this high-throughput platform to perform an 18-plex assessment of HER2 ICD/ECD, cytotoxic T-cell infiltration and other structural and signaling proteins in a cohort of patients treated with trastuzumab to discover associations with trastuzumab benefit. EXPERIMENTAL
designAn antibody panel for detection of 18 targets (pan-cytokeratin, HER2 ICD, HER2 ECD, CD8, vimentin, cytokeratin 7, β-catenin, HER3, MET, EGFR, ERK 1-2, MEK 1-2, PTEN, PI3K p110 α, Akt, mTOR, Ki67, and Histone H3) was used with a selection of trastuzumab-treated patients from the Hellenic Cooperative Oncology Group 10/05 trial (
resultsPatients that recurred after adjuvant treatment with trastuzumab trended toward a decreased fraction of HER2 ECD pixels over threshold compared with cases without recurrence (
conclusionsThe proximity of CD8 cells as a function of the expression of the ECD of HER2 provides further evidence for the role of the immune system in the mechanism of action of trastuzumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.